Global Opioid-Induced Constipation Market Growth 2022-2028

SKU ID : LPI-19835086 | Publishing Date : 04-Jan-2022 | No. of pages : 106

Detailed TOC of Global Opioid-Induced Constipation Market Growth 2022-2028

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Opioid-Induced Constipation Annual Sales 2017-2028
        2.1.2 World Current & Future Analysis for Opioid-Induced Constipation by Geographic Region, 2017, 2022 & 2028
        2.1.3 World Current & Future Analysis for Opioid-Induced Constipation by Country/Region, 2017, 2022 & 2028
    2.2 Opioid-Induced Constipation Segment by Type
        2.2.1 Methylnaltrexone Bromide
        2.2.2 Lubiprostone
        2.2.3 Naloxegol
        2.2.4 Others
    2.3 Opioid-Induced Constipation Sales by Type
        2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
        2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2017-2022)
        2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2017-2022)
    2.4 Opioid-Induced Constipation Segment by Application
        2.4.1 Hospital
        2.4.2 Pharmacy
        2.4.3 Other
    2.5 Opioid-Induced Constipation Sales by Application
        2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2017-2022)
        2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2017-2022)
        2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2017-2022)
3 Global Opioid-Induced Constipation by Company
    3.1 Global Opioid-Induced Constipation Breakdown Data by Company
        3.1.1 Global Opioid-Induced Constipation Annual Sales by Company (2020-2022)
        3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2020-2022)
    3.2 Global Opioid-Induced Constipation Annual Revenue by Company (2020-2022)
        3.2.1 Global Opioid-Induced Constipation Revenue by Company (2020-2022)
        3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2022)
    3.3 Global Opioid-Induced Constipation Sale Price by Company
    3.4 Key Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution
        3.4.2 Players Opioid-Induced Constipation Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    3.6 New Products and Potential Entrants
    3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Opioid-Induced Constipation by Geographic Region
    4.1 World Historic Opioid-Induced Constipation Market Size by Geographic Region (2017-2022)
        4.1.1 Global Opioid-Induced Constipation Annual Sales by Geographic Region (2017-2022)
        4.1.2 Global Opioid-Induced Constipation Annual Revenue by Geographic Region
    4.2 World Historic Opioid-Induced Constipation Market Size by Country/Region (2017-2022)
        4.2.1 Global Opioid-Induced Constipation Annual Sales by Country/Region (2017-2022)
        4.2.2 Global Opioid-Induced Constipation Annual Revenue by Country/Region
    4.3 Americas Opioid-Induced Constipation Sales Growth
    4.4 APAC Opioid-Induced Constipation Sales Growth
    4.5 Europe Opioid-Induced Constipation Sales Growth
    4.6 Middle East & Africa Opioid-Induced Constipation Sales Growth
5 Americas
    5.1 Americas Opioid-Induced Constipation Sales by Country
        5.1.1 Americas Opioid-Induced Constipation Sales by Country (2017-2022)
        5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2017-2022)
    5.2 Americas Opioid-Induced Constipation Sales by Type
    5.3 Americas Opioid-Induced Constipation Sales by Application
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
6 APAC
    6.1 APAC Opioid-Induced Constipation Sales by Region
        6.1.1 APAC Opioid-Induced Constipation Sales by Region (2017-2022)
        6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2017-2022)
    6.2 APAC Opioid-Induced Constipation Sales by Type
    6.3 APAC Opioid-Induced Constipation Sales by Application
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan
7 Europe
    7.1 Europe Opioid-Induced Constipation by Country
        7.1.1 Europe Opioid-Induced Constipation Sales by Country (2017-2022)
        7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2017-2022)
    7.2 Europe Opioid-Induced Constipation Sales by Type
    7.3 Europe Opioid-Induced Constipation Sales by Application
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
8 Middle East & Africa
    8.1 Middle East & Africa Opioid-Induced Constipation by Country
        8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2017-2022)
        8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2017-2022)
    8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type
    8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries
9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Opioid-Induced Constipation
    10.3 Manufacturing Process Analysis of Opioid-Induced Constipation
    10.4 Industry Chain Structure of Opioid-Induced Constipation
11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Opioid-Induced Constipation Distributors
    11.3 Opioid-Induced Constipation Customer
12 World Forecast Review for Opioid-Induced Constipation by Geographic Region
    12.1 Global Opioid-Induced Constipation Market Size Forecast by Region
        12.1.1 Global Opioid-Induced Constipation Forecast by Region (2023-2028)
        12.1.2 Global Opioid-Induced Constipation Annual Revenue Forecast by Region (2023-2028)
    12.2 Americas Forecast by Country
    12.3 APAC Forecast by Region
    12.4 Europe Forecast by Country
    12.5 Middle East & Africa Forecast by Country
    12.6 Global Opioid-Induced Constipation Forecast by Type
    12.7 Global Opioid-Induced Constipation Forecast by Application
13 Key Players Analysis
    13.1 Takeda Pharmaceuticals
        13.1.1 Takeda Pharmaceuticals Company Information
        13.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
        13.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.1.4 Takeda Pharmaceuticals Main Business Overview
        13.1.5 Takeda Pharmaceuticals Latest Developments
    13.2 Bayer
        13.2.1 Bayer Company Information
        13.2.2 Bayer Opioid-Induced Constipation Product Offered
        13.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.2.4 Bayer Main Business Overview
        13.2.5 Bayer Latest Developments
    13.3 Sanofi
        13.3.1 Sanofi Company Information
        13.3.2 Sanofi Opioid-Induced Constipation Product Offered
        13.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.3.4 Sanofi Main Business Overview
        13.3.5 Sanofi Latest Developments
    13.4 Mallinckrodt
        13.4.1 Mallinckrodt Company Information
        13.4.2 Mallinckrodt Opioid-Induced Constipation Product Offered
        13.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.4.4 Mallinckrodt Main Business Overview
        13.4.5 Mallinckrodt Latest Developments
    13.5 Salix (Bausch Health)
        13.5.1 Salix (Bausch Health) Company Information
        13.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Offered
        13.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.5.4 Salix (Bausch Health) Main Business Overview
        13.5.5 Salix (Bausch Health) Latest Developments
    13.6 AstraZeneca
        13.6.1 AstraZeneca Company Information
        13.6.2 AstraZeneca Opioid-Induced Constipation Product Offered
        13.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.6.4 AstraZeneca Main Business Overview
        13.6.5 AstraZeneca Latest Developments
    13.7 Progenics Pharmaceuticals
        13.7.1 Progenics Pharmaceuticals Company Information
        13.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
        13.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.7.4 Progenics Pharmaceuticals Main Business Overview
        13.7.5 Progenics Pharmaceuticals Latest Developments
    13.8 Purdue Pharm
        13.8.1 Purdue Pharm Company Information
        13.8.2 Purdue Pharm Opioid-Induced Constipation Product Offered
        13.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.8.4 Purdue Pharm Main Business Overview
        13.8.5 Purdue Pharm Latest Developments
    13.9 Nektar Therapeutics
        13.9.1 Nektar Therapeutics Company Information
        13.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Offered
        13.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.9.4 Nektar Therapeutics Main Business Overview
        13.9.5 Nektar Therapeutics Latest Developments
    13.10 Daiichi Sankyo
        13.10.1 Daiichi Sankyo Company Information
        13.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Offered
        13.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.10.4 Daiichi Sankyo Main Business Overview
        13.10.5 Daiichi Sankyo Latest Developments
    13.11 Prestige
        13.11.1 Prestige Company Information
        13.11.2 Prestige Opioid-Induced Constipation Product Offered
        13.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.11.4 Prestige Main Business Overview
        13.11.5 Prestige Latest Developments
    13.12 GSK
        13.12.1 GSK Company Information
        13.12.2 GSK Opioid-Induced Constipation Product Offered
        13.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.12.4 GSK Main Business Overview
        13.12.5 GSK Latest Developments
    13.13 Shionogi
        13.13.1 Shionogi Company Information
        13.13.2 Shionogi Opioid-Induced Constipation Product Offered
        13.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2020-2022)
        13.13.4 Shionogi Main Business Overview
        13.13.5 Shionogi Latest Developments
14 Research Findings and Conclusion

List of Figures, Tables and Charts Available in Global Opioid-Induced Constipation Market Growth 2022-2028

List of Tables
    Table 1. Opioid-Induced Constipation Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
    Table 2. Opioid-Induced Constipation Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
    Table 3. Major Players of Methylnaltrexone Bromide
    Table 4. Major Players of Lubiprostone
    Table 5. Major Players of Naloxegol
    Table 6. Major Players of Others
    Table 7. Global Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 8. Global Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
    Table 9. Global Opioid-Induced Constipation Revenue by Type (2017-2022) & ($ million)
    Table 10. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2022)
    Table 11. Global Opioid-Induced Constipation Sale Price by Type (2017-2022) & (USD/Unit)
    Table 12. Global Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 13. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Table 14. Global Opioid-Induced Constipation Revenue by Application (2017-2022)
    Table 15. Global Opioid-Induced Constipation Revenue Market Share by Application (2017-2022)
    Table 16. Global Opioid-Induced Constipation Sale Price by Application (2017-2022) & (USD/Unit)
    Table 17. Global Opioid-Induced Constipation Sales by Company (2020-2022) & (K Units)
    Table 18. Global Opioid-Induced Constipation Sales Market Share by Company (2020-2022)
    Table 19. Global Opioid-Induced Constipation Revenue by Company (2020-2022) ($ Millions)
    Table 20. Global Opioid-Induced Constipation Revenue Market Share by Company (2020-2022)
    Table 21. Global Opioid-Induced Constipation Sale Price by Company (2020-2022) & (USD/Unit)
    Table 22. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area
    Table 23. Players Opioid-Induced Constipation Products Offered
    Table 24. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 25. New Products and Potential Entrants
    Table 26. Mergers & Acquisitions, Expansion
    Table 27. Global Opioid-Induced Constipation Sales by Geographic Region (2017-2022) & (K Units)
    Table 28. Global Opioid-Induced Constipation Sales Market Share Geographic Region (2017-2022)
    Table 29. Global Opioid-Induced Constipation Revenue by Geographic Region (2017-2022) & ($ millions)
    Table 30. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region (2017-2022)
    Table 31. Global Opioid-Induced Constipation Sales by Country/Region (2017-2022) & (K Units)
    Table 32. Global Opioid-Induced Constipation Sales Market Share by Country/Region (2017-2022)
    Table 33. Global Opioid-Induced Constipation Revenue by Country/Region (2017-2022) & ($ millions)
    Table 34. Global Opioid-Induced Constipation Revenue Market Share by Country/Region (2017-2022)
    Table 35. Americas Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 36. Americas Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
    Table 37. Americas Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
    Table 38. Americas Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
    Table 39. Americas Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 40. Americas Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
    Table 41. Americas Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 42. Americas Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Table 43. APAC Opioid-Induced Constipation Sales by Region (2017-2022) & (K Units)
    Table 44. APAC Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
    Table 45. APAC Opioid-Induced Constipation Revenue by Region (2017-2022) & ($ Millions)
    Table 46. APAC Opioid-Induced Constipation Revenue Market Share by Region (2017-2022)
    Table 47. APAC Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 48. APAC Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
    Table 49. APAC Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 50. APAC Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Table 51. Europe Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 52. Europe Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
    Table 53. Europe Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
    Table 54. Europe Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
    Table 55. Europe Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 56. Europe Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
    Table 57. Europe Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 58. Europe Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Table 59. Middle East & Africa Opioid-Induced Constipation Sales by Country (2017-2022) & (K Units)
    Table 60. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2017-2022)
    Table 61. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2017-2022) & ($ Millions)
    Table 62. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2017-2022)
    Table 63. Middle East & Africa Opioid-Induced Constipation Sales by Type (2017-2022) & (K Units)
    Table 64. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type (2017-2022)
    Table 65. Middle East & Africa Opioid-Induced Constipation Sales by Application (2017-2022) & (K Units)
    Table 66. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Table 67. Key Market Drivers & Growth Opportunities of Opioid-Induced Constipation
    Table 68. Key Market Challenges & Risks of Opioid-Induced Constipation
    Table 69. Key Industry Trends of Opioid-Induced Constipation
    Table 70. Opioid-Induced Constipation Raw Material
    Table 71. Key Suppliers of Raw Materials
    Table 72. Opioid-Induced Constipation Distributors List
    Table 73. Opioid-Induced Constipation Customer List
    Table 74. Global Opioid-Induced Constipation Sales Forecast by Region (2023-2028) & (K Units)
    Table 75. Global Opioid-Induced Constipation Sales Market Forecast by Region
    Table 76. Global Opioid-Induced Constipation Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 77. Global Opioid-Induced Constipation Revenue Market Share Forecast by Region (2023-2028)
    Table 78. Americas Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
    Table 79. Americas Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 80. APAC Opioid-Induced Constipation Sales Forecast by Region (2023-2028) & (K Units)
    Table 81. APAC Opioid-Induced Constipation Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 82. Europe Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
    Table 83. Europe Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 84. Middle East & Africa Opioid-Induced Constipation Sales Forecast by Country (2023-2028) & (K Units)
    Table 85. Middle East & Africa Opioid-Induced Constipation Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 86. Global Opioid-Induced Constipation Sales Forecast by Type (2023-2028) & (K Units)
    Table 87. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2023-2028)
    Table 88. Global Opioid-Induced Constipation Revenue Forecast by Type (2023-2028) & ($ Millions)
    Table 89. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2023-2028)
    Table 90. Global Opioid-Induced Constipation Sales Forecast by Application (2023-2028) & (K Units)
    Table 91. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2023-2028)
    Table 92. Global Opioid-Induced Constipation Revenue Forecast by Application (2023-2028) & ($ Millions)
    Table 93. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2023-2028)
    Table 94. Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 95. Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered
    Table 96. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 97. Takeda Pharmaceuticals Main Business
    Table 98. Takeda Pharmaceuticals Latest Developments
    Table 99. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 100. Bayer Opioid-Induced Constipation Product Offered
    Table 101. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 102. Bayer Main Business
    Table 103. Bayer Latest Developments
    Table 104. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 105. Sanofi Opioid-Induced Constipation Product Offered
    Table 106. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 107. Sanofi Main Business
    Table 108. Sanofi Latest Developments
    Table 109. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 110. Mallinckrodt Opioid-Induced Constipation Product Offered
    Table 111. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 112. Mallinckrodt Main Business
    Table 113. Mallinckrodt Latest Developments
    Table 114. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 115. Salix (Bausch Health) Opioid-Induced Constipation Product Offered
    Table 116. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 117. Salix (Bausch Health) Main Business
    Table 118. Salix (Bausch Health) Latest Developments
    Table 119. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 120. AstraZeneca Opioid-Induced Constipation Product Offered
    Table 121. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 122. AstraZeneca Main Business
    Table 123. AstraZeneca Latest Developments
    Table 124. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 125. Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered
    Table 126. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 127. Progenics Pharmaceuticals Main Business
    Table 128. Progenics Pharmaceuticals Latest Developments
    Table 129. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 130. Purdue Pharm Opioid-Induced Constipation Product Offered
    Table 131. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 132. Purdue Pharm Main Business
    Table 133. Purdue Pharm Latest Developments
    Table 134. Nektar Therapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 135. Nektar Therapeutics Opioid-Induced Constipation Product Offered
    Table 136. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 137. Nektar Therapeutics Main Business
    Table 138. Nektar Therapeutics Latest Developments
    Table 139. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 140. Daiichi Sankyo Opioid-Induced Constipation Product Offered
    Table 141. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 142. Daiichi Sankyo Main Business
    Table 143. Daiichi Sankyo Latest Developments
    Table 144. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 145. Prestige Opioid-Induced Constipation Product Offered
    Table 146. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 147. Prestige Main Business
    Table 148. Prestige Latest Developments
    Table 149. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 150. GSK Opioid-Induced Constipation Product Offered
    Table 151. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 152. GSK Main Business
    Table 153. GSK Latest Developments
    Table 154. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors
    Table 155. Shionogi Opioid-Induced Constipation Product Offered
    Table 156. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
    Table 157. Shionogi Main Business
    Table 158. Shionogi Latest Developments
List of Figures
    Figure 1. Picture of Opioid-Induced Constipation
    Figure 2. Opioid-Induced Constipation Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2017-2028 (K Units)
    Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2017-2028 ($ Millions)
    Figure 8. Opioid-Induced Constipation Sales by Region (2021 & 2028) & ($ millions)
    Figure 9. Product Picture of Methylnaltrexone Bromide
    Figure 10. Product Picture of Lubiprostone
    Figure 11. Product Picture of Naloxegol
    Figure 12. Product Picture of Others
    Figure 13. Global Opioid-Induced Constipation Sales Market Share by Type in 2021
    Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Type (2017-2022)
    Figure 15. Opioid-Induced Constipation Consumed in Hospital
    Figure 16. Global Opioid-Induced Constipation Market: Hospital (2017-2022) & (K Units)
    Figure 17. Opioid-Induced Constipation Consumed in Pharmacy
    Figure 18. Global Opioid-Induced Constipation Market: Pharmacy (2017-2022) & (K Units)
    Figure 19. Opioid-Induced Constipation Consumed in Other
    Figure 20. Global Opioid-Induced Constipation Market: Other (2017-2022) & (K Units)
    Figure 21. Global Opioid-Induced Constipation Sales Market Share by Application (2017-2022)
    Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Application in 2021
    Figure 23. Opioid-Induced Constipation Revenue Market by Company in 2021 ($ Million)
    Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Company in 2021
    Figure 25. Global Opioid-Induced Constipation Sales Market Share by Geographic Region (2017-2022)
    Figure 26. Global Opioid-Induced Constipation Revenue Market Share by Geographic Region in 2021
    Figure 27. Global Opioid-Induced Constipation Sales Market Share by Region (2017-2022)
    Figure 28. Global Opioid-Induced Constipation Revenue Market Share by Country/Region in 2021
    Figure 29. Americas Opioid-Induced Constipation Sales 2017-2022 (K Units)
    Figure 30. Americas Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
    Figure 31. APAC Opioid-Induced Constipation Sales 2017-2022 (K Units)
    Figure 32. APAC Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
    Figure 33. Europe Opioid-Induced Constipation Sales 2017-2022 (K Units)
    Figure 34. Europe Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
    Figure 35. Middle East & Africa Opioid-Induced Constipation Sales 2017-2022 (K Units)
    Figure 36. Middle East & Africa Opioid-Induced Constipation Revenue 2017-2022 ($ Millions)
    Figure 37. Americas Opioid-Induced Constipation Sales Market Share by Country in 2021
    Figure 38. Americas Opioid-Induced Constipation Revenue Market Share by Country in 2021
    Figure 39. United States Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 40. Canada Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 41. Mexico Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 42. Brazil Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 43. APAC Opioid-Induced Constipation Sales Market Share by Region in 2021
    Figure 44. APAC Opioid-Induced Constipation Revenue Market Share by Regions in 2021
    Figure 45. China Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 46. Japan Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 47. South Korea Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 48. Southeast Asia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 49. India Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 50. Australia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 51. Europe Opioid-Induced Constipation Sales Market Share by Country in 2021
    Figure 52. Europe Opioid-Induced Constipation Revenue Market Share by Country in 2021
    Figure 53. Germany Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 54. France Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 55. UK Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 56. Italy Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 57. Russia Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 58. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country in 2021
    Figure 59. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country in 2021
    Figure 60. Egypt Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 61. South Africa Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 62. Israel Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 63. Turkey Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 64. GCC Country Opioid-Induced Constipation Revenue Growth 2017-2022 ($ Millions)
    Figure 65. Manufacturing Cost Structure Analysis of Opioid-Induced Constipation in 2021
    Figure 66. Manufacturing Process Analysis of Opioid-Induced Constipation
    Figure 67. Industry Chain Structure of Opioid-Induced Constipation
    Figure 68. Channels of Distribution
    Figure 69. Distributors Profiles